Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 13/20 | 1.00 |
| ▸ | ABL1 | P00519 | 7/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 5/20 | 1.00 |
| ▸ | PRKD2 | Q9BZL6 | 5/20 | 1.00 |
| ▸ | PRKD1 | Q15139 | 4/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 4/20 | 1.00 |
| ▸ | FYN | P06241 | 4/20 | 1.00 |
| ▸ | CSK | P41240 | 3/20 | 1.00 |
| ▸ | MAPK8 | P45983 | 3/20 | 1.00 |
| ▸ | CSNK1D | P48730 | 3/20 | 1.00 |
| ▸ | CDK2 | P24941 | 2/20 | 1.00 |
| ▸ | CAMK2A | Q9UQM7 | 2/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 1/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.64 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.64 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.64 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.64 |
| ▸ | PRKDC | P78527 | 1/20 | 0.64 |
| ▸ | PRKACA | P17612 | 3/20 | 0.64 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL173288 | 1.00 | SRC (1.00) | SRCABL1PRKD3PRKD2PRKD1 | |
| SCHEMBL29389632 | 1.00 | SRC (1.00) | SRCABL1PRKD3PRKD2PRKD1 | |
| Hydrochloric Acid SCHEMBL7037036 | 0.99 | SRC (0.98) | SRCABL1PRKD3PRKD2PRKD1 | |
| Hydrochloric Acid SCHEMBL30682158 | 0.99 | SRC (0.98) | SRCABL1PRKD3PRKD2PRKD1 | |
| Hydrochloric Acid SCHEMBL31031035 | 0.99 | SRC (0.98) | SRCABL1PRKD3PRKD2PRKD1 | |
| SCHEMBL12551746 | 0.85 | SRC (0.74) | SRCABL1PRKD3PRKD2PRKD1 | |
| SCHEMBL13019875 | 0.84 | SRC (0.73) | SRCABL1PRKD3PRKD2PRKD1 | |
| SCHEMBL12551755 | 0.84 | SRC (0.73) | SRCABL1PRKD3PRKD2PRKD1 | |
| SCHEMBL3611430 | 0.84 | SRC (0.72) | SRCABL1PRKD3PRKD2PRKD1 | |
| SCHEMBL12551780 | 0.82 | SRC (0.70) | SRCABL1PRKD3PRKD2PRKD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2026-04-07 | — | — | US | claimed |
| WO-2025202361-A1 | ANTI-GPC1 ANTIBODIES AND USES THEREOF | ADCENDO APS (DK) | 2025-10-02 | — | — | WO | claimed |
| US-20250302977-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING HUMANIZED ANTIBODIES TARGETING UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTOR ASSOCIATED PROTEIN (UPARAP) | RIGSHOSPITALET (DK) | 2025-10-02 | — | — | US | claimed |
| US-20250262167-A1 | COMPOUNDS, TARGETS AND PATHWAYS FOR MACROPHAGE MODULATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2025-08-21 | — | — | US | claimed |
| WO-2025099152-A1 | ANTIBODIES AND MOLECULAR CONJUGATES THEREOF TARGETING UPAR | RIGSHOSPITALET (DK) | 2025-05-15 | — | — | WO | claimed |
| CN-119072322-A | Methods and compositions for preventing or treating myopia | 坪田实验室股份有限公司 | 2024-12-03 | — | — | CN | claimed |
| US-20240358678-A1 | METHODS AND COMPOSITIONS FOR ENHANCING CHEMOTHERAPEUTIC DRUG UPTAKE INTO BRAIN TUMORS | BROWN UNIVERSITY | 2024-10-31 | — | — | US | claimed |
| WO-2024182413-A1 | THERAPEUTIC METHODS | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2024-09-06 | — | — | WO | claimed |
| CN-118141921-A | Use of CAMK2 inhibitors for the preparation of a medicament for reducing resistance to EGFR-driven cancers | 四川大学 | 2024-06-07 | — | — | CN | claimed |
| EP-4363447-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING HUMANIZED ANTIBODIES TARGETING UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTOR ASSOCIATED PROTEIN (UPARAP) | Rigshospitalet (DK) | 2024-05-08 | — | — | EP | claimed |
| US-20230310380-A1 | METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES | GLAZIER ALAN NEIL (US) | 2023-10-05 | — | — | US | claimed |
| EP-4213901-A1 | COMPOUNDS, TARGETS AND PATHWAYS FOR MACROPHAGE MODULATION | Massachusetts Institute of Technology (US) | 2023-07-26 | — | — | EP | claimed |
| CN-116390760-A | Compositions and methods for increasing sensitivity of cancer cells to alternating electric fields | 诺沃库勒有限责任公司 | 2023-07-04 | — | — | CN | claimed |
| CN-116368384-A | Compounds, targets and pathways for macrophage modulation | 麻省理工学院 | 2023-06-30 | — | — | CN | claimed |
| EP-4188380-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | Novocure GmbH (CH) | 2023-06-07 | — | — | EP | claimed |
| WO-2023275112-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING HUMANIZED ANTIBODIES TARGETING UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTOR ASSOCIATED PROTEIN (UPARAP) | RIGSHOSPITALET (DK) | 2023-01-05 | — | — | WO | claimed |
| US-20220096818-A1 | Compositions And Methods For Increasing Cancer Cell Sensitivity To Alternating Electric Fields | BIOPHARMA CREDIT PLC (GB) | 2022-03-31 | — | — | US | claimed |
| WO-2022060466-A1 | COMPOUNDS, TARGETS AND PATHWAYS FOR MACROPHAGE MODULATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-03-24 | — | — | WO | claimed |
| US-20220087950-A1 | COMPOUNDS, TARGETS AND PATHWAYS FOR MACROPHAGE MODULATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-24 | — | — | US | claimed |
| WO-2022029628-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2022-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240358678-A1 | METHODS AND COMPOSITIONS FOR ENHANCING CHEMOTHERAPEUTIC DRUG UPTAKE INTO BRAIN TUMORS | SLC19A1, SLC5A7, FABP7 | SRC 894/4885ABL1 971/4885PRKD3 3178/4885 |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | PTK2, GSK3B, MTOR | SRC 10/4885ABL1 751/4885PRKD3 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.